Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

July 15, 2021

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

July 08, 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

July 07, 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

July 06, 2021

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

June 23, 2021

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

June 23, 2021

Peter Martin, MD, discusses discrepancies in real-world patterns of care for patients with MCL and what can be done to overcome them.

June 16, 2021

Peter Martin, MD, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma.

May 18, 2021

Roy S. Herbst, MD, PhD, was inspired to become an oncologist during his first week as an MD/PhD candidate at Cornell University and The Rockefeller University, thanks in part to Ralph L. Nachman, MD, longtime chair of Weill Department of Medicine at Weill Cornell Medical College.

April 14, 2021

Scott T. Tagawa, MD, MS, FACP, discusses the FDA approval of sacituzumab govitecan-hziy in advanced urothelial carcinoma.

March 30, 2021

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

March 19, 2021

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

March 19, 2021

Ghaith Abu-Zeinah, MD, discusses utilizing interferon-alpha in patients with polycythemia vera.

March 17, 2021

Peter Martin, MD, discusses treatment considerations for patients with mantle cell lymphoma.

March 11, 2021

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

March 05, 2021

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

March 01, 2021

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

March 01, 2021

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

February 17, 2021

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

February 12, 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

January 29, 2021

BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.